Skip to content
Open access

CA 15.3, Metastatic Burden, and Overall Survival in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: Real-World Evidence from Peru

Aug 2026 · Biomedicines · Vol 14, pp. 1930 · 0 citations · 34 references
Medicine

TL;DR

Elevated baseline CA 15.3 was associated with greater metastatic burden and shorter OS, and baseline/follow-up patterns were exploratory because the sampling was not standardized, and should be interpreted as an adjunct to clinical and radiological assessment.

Abstract

Background/Objectives: Serum cancer antigen 15.3 (CA 15.3) is frequently measured in advanced breast cancer, but its prognostic significance after adjusting for established clinical factors remains incompletely characterized in Latin American populations. We evaluated the association of baseline CA 15.3 with metastatic burden and overall survival (OS) in hormone receptor-positive/HER2-negative advanced breast cancer and descriptively explored baseline/follow-up patterns. Methods: We retrospectively evaluated 127 women treated at a Peruvian public oncology institution between 2018 and 2024, with CA 15.3 levels ≥32.4 U/mL being considered elevated. Baseline associations were assessed using multivariable logistic regression, and OS was evaluated using Kaplan–Meier estimates and Cox proportional hazards regression adjusted for age, ECOG performance status, de novo versus recurrent disease, luminal subtype, first-line treatment, number of metastatic sites, and metastatic site. Results: Baseline CA 15.3 was elevated in 41/127 patients (32.3%) and was independently associated with postmenopausal status (OR: 3.27; 95% CI, 1.33–9.03; p = 0.014) and ≥2 metastatic sites (OR: 2.72; 95% CI, 1.24–6.10; p = 0.013). Median OS was 55 months (95% CI, 43–78), while elevated baseline CA 15.3 was associated with shorter OS (41 vs. 65 months; log-rank p = 0.024) and remained independently associated with shorter OS after multivariable adjustment (adjusted HR: 3.42; 95% CI, 1.63–7.19; p = 0.001). Conclusions: Elevated baseline CA 15.3 was associated with greater metastatic burden and shorter OS, and baseline/follow-up patterns were exploratory because the sampling was not standardized. Thus, CA 15.3 should be interpreted as an adjunct to clinical and radiological assessment.

Read PDF

Similar papers

Open access Sep 2026

Tumor regression grades in locally advanced gastroesophageal adenocarcinoma: associations with survival, pathological risk factors, and molecular biomarkers in a 19-year real-world cohort

In this long-term real-world cohort, Mandard TRG was associated with survival, although its prognostic impact appears closely linked to pathological stage and molecular context, particularly in the evolving era of perioperative chemo-immunotherapy.

H. Puhr, B. Mozayani, M. Korpan et al. · 0 citations
Open access Sep 2026

Real-world characteristics and invasive disease-free survival of resected patients with HR-positive/HER2-negative early breast cancer: evidence from German population-based cancer registries

Background Hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) tumors are the most prevalent subtypes of early breast cancer (eBC). Despite the generally favorable prognosis, a relevant proportion experiences invasive disease events following surgery. We aimed t...

P. Grieger, M. Y. Beykloo, C. Lee et al. · 0 citations
Review Open access Sep 2026

Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Background/Objectives: The prognostic nutritional index (PNI) has been associated with outcome in metastatic breast cancer, but studies in CDK4/6 inhibitor-treated patients have used cohort-derived thresholds and examined only the pretreatment value. We assessed the PNI as a continuous variable, compared it with inflam...

E. Çoban, A. Kurt, Fırat Akagündüz et al. · 0 citations
Open access Sep 2026

Development and internal validation of prognostic nomograms for overall and breast cancer-specific survival in de novo stage IV HER2-positive breast cancer.

The nomograms showed good internal discrimination and may support individualized prognostic assessment once initial treatment information is available, and 5-year estimates should be interpreted cautiously given the median follow-up of 27 months.

Xiao-Jie Yu, De-Yuan Fu, L. Yao · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.